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The clinical application of gefitinib has unexpectedly highlighted racial differences among patients with non–small-cell lung cancers since its initial clinical development.1 
This first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
demonstrated greater efficacy in East-Asian patients compared with white patients. Later 
studies revealed that this difference was on the basis of differences in EGFR mutation 
frequency between these two ethnic populations.2–4 Other studies further analyzed EGFR 
mutation frequencies in black patients, reporting a lower (or similar) frequency of this 
mutation compared with white patients.5–7 The cause of EGFR mutation is currently unclear. 
However, evidence suggests that racial or genetic differences may play a more important 
role in their occurrence than differences in lifestyle, such as diet, or geographic location. 
For example, East-Asians born or living in the United States have a high EGFR mutation 
rate, similar to that of East-Asians living in their native countries.8 In addition, the recent 
PIONEER study (NCT01185314) observed a lower EGFR mutation frequency in Indian 
patients (22.2%) comparable with that of white patients,9 both of which are classified as 
Caucasians. The frequencies of other mutations in non–small-cell lung cancers, such as 
KRAS or STK11, have also been reported to differ among ethnic groups.6,7,10
Recent developments in next-generation sequencing techniques have detected high 
rates of genetic alterations, including EGFR and KRAS mutations, in human lung can-
cers.11 Does the mutational profiling of lung cancers differ between ethnic groups? In 
this issue of the Journal of Thoracic Oncology, Bollig-Fischer et al.12 compared genetic 
differences between 335 white and 137 black patients using a matrix-assisted laser 
desorption/ionization time-of-flight mass-spectrometry approach in relation to 214 cod-
ing mutations in 26 cancer-related genes previously identified in non–small-cell lung 
cancers. Histologically, the black patient cohort demonstrated a higher rate of adenocar-
cinoma (67%) compared with the white patient cohort (48%). One of the most interest-
ing findings was the difference in mutation rates between these two ethnic groups; 32% 
of black patients and 41% of white patients harbored at least one mutation in the 26 
genes studied. The odds ratio of black patients having one or more mutations, adjusted 
for covariates using a logistic regression model, was 0.582 (95% confidence interval, 
0.363–0.933; p = 0.025), suggesting a lower mutation rate in black patients compared 
with white patients. Although the reason for this discrepancy in mutation rates between 
black and white patients is unclear, it can be hypothesized that fewer accumulated muta-
tions may be needed to cause lung cancers in black people compared with white people. 
This could at least partly explain the earlier onset of lung cancers in black patients12; the 
mean age at diagnosis was 66 years in African Americans compared with 71 years in 
whites.7 However, despite lower overall mutation rates in black patients, further analyses 
identified a higher incidence of EGFR exon 19 deletion in female black compared with 
female white patients (odds ratio, 3.914; p = 0.048). Although another study has shown 
similar result,13 the reason(s) underlying this phenomenon remain unclear.
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Bollig-Fischer et al.12 also analyzed tumor specimens 
for single nucleotide polymorphisms. The frequencies of 
these single nucleotide polymorphisms in tumor samples 
from black and white patients correlated with their reported 
frequencies in the respective ethnic groups in the general pop-
ulation in the United States. However, NOTCH1 V1671I (p = 
0.01) and MET N375S (p = 0.076) polymorphisms were more 
frequent in patients with cancer compared with the general 
population in black patients and white patients, respectively. 
Further studies are needed to explore the biological and clini-
cal implications of these differences.
One limitation of this study was that the cohort mainly 
consisted of smokers (<10% were never smokers in both 
ethnic groups). Tobacco smoke contains several carcino-
gens that can form stable covalent DNA adducts and induce 
DNA single-strand breaks, leading to higher mutation rates 
in lung cancers in smokers compared with nonsmokers. The 
genetic differences observed in the study by Bollig-Fischer 
et al. therefore represent a combination of racial differences 
in the lung cancers themselves and racial differences in sus-
ceptibility to tobacco smoking. It is also debatable whether 
lung cancers in black patients can be considered as a single 
disease, given that many studies, including genome-wide 
studies, have indicated higher levels of genetic diversity in 
African populations, including African Americans, com-
pared with non-Africans. The genetic diversity among black 
patients may thus be higher than that within other ethnic 
groups.14
In summary, the study by Bollig-Fisher et al. repre-
sents an attractive approach; however, its findings are largely 
observational, and the underlying backgrounds and clinical 
implications of their findings are unclear. Further analyses 
based on their findings are necessary. Racial differences in 
physical features among humans can be large, despite very 
small genetic differences between ethnic groups. In con-
trast, it is interesting that racial differences in lung cancer 
genetics are relatively large, despite indistinguishably small 
differences in the microscopic morphologies of lung can-
cers among ethnic groups.
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